Debendra Pattanaik1, Jay Adam Lieberman2. 1. Department of Internal Medicine, Division of Rheumatology, The University of Tennessee Health Science Center, 51 North Dunlap, Suite 400, Memphis, TN, 38105, USA. 2. Department of Pediatrics, Division of Allergy & Immunology, The University of Tennessee Health Science Center, 51 North Dunlap, Suite 400, Memphis, TN, 38105, USA. jlieber1@uthsc.edu.
Abstract
PURPOSE OF REVIEW: The aims of this study are to update the clinician on current understanding of angioedema as it presents in the pediatric population and to review proper diagnostic techniques and treatment modalities for various types of angioedema. RECENT FINDINGS: Angioedema is still best classified by whether it is likely histaminergic or kinin-mediated. New guidelines have been published around the world to help diagnose and treat both forms (urticaria/angioedema and hereditary angioedema). The vast majority of the studies on treatment have been conducted in the adult population; however, there are data available in the pediatric population. In the realm of hereditary angioedema, there are multiple new therapies that have been studied in the pediatric population (down to 2 years in some studies) in recent years and offer the clinician options for treatment. Angioedema (whether occurring with or without urticaria) is common in the pediatric population. The majority of the recent studies has been conducted in hereditary angioedema, and now, the clinician should have various options to treat all forms of angioedema. Many treatment options, especially for hereditary angioedema, are further being examined specifically in the pediatric population.
PURPOSE OF REVIEW: The aims of this study are to update the clinician on current understanding of angioedema as it presents in the pediatric population and to review proper diagnostic techniques and treatment modalities for various types of angioedema. RECENT FINDINGS:Angioedema is still best classified by whether it is likely histaminergic or kinin-mediated. New guidelines have been published around the world to help diagnose and treat both forms (urticaria/angioedema and hereditary angioedema). The vast majority of the studies on treatment have been conducted in the adult population; however, there are data available in the pediatric population. In the realm of hereditary angioedema, there are multiple new therapies that have been studied in the pediatric population (down to 2 years in some studies) in recent years and offer the clinician options for treatment. Angioedema (whether occurring with or without urticaria) is common in the pediatric population. The majority of the recent studies has been conducted in hereditary angioedema, and now, the clinician should have various options to treat all forms of angioedema. Many treatment options, especially for hereditary angioedema, are further being examined specifically in the pediatric population.
Authors: David M Lang; Werner Aberer; Jonathan A Bernstein; Hiok Hee Chng; Anete Sevciovic Grumach; Michihiro Hide; Marcus Maurer; Richard Weber; Bruce Zuraw Journal: Ann Allergy Asthma Immunol Date: 2012-12 Impact factor: 6.347
Authors: Henriette Farkas; Avner Reshef; Werner Aberer; Teresa Caballero; Laura McCarthy; James Hao; Wolfram Nothaft; Jennifer Schranz; Jonathan A Bernstein; H Henry Li Journal: J Allergy Clin Immunol Pract Date: 2017-06-07
Authors: Marc A Riedl; Jonathan A Bernstein; Henry Li; Avner Reshef; William Lumry; Dumitru Moldovan; Henriette Farkas; Robyn Levy; James Baker; Yun Hardiman; Mark C Totoritis; Anurag Relan; Marco Cicardi Journal: Ann Allergy Asthma Immunol Date: 2014-01-07 Impact factor: 6.347
Authors: Timothy J Craig; Robyn J Levy; Richard L Wasserman; Againdra K Bewtra; David Hurewitz; Krystyna Obtułowicz; Avner Reshef; Bruce Ritchie; Dumitru Moldovan; Todor Shirov; Vesna Grivcheva-Panovska; Peter C Kiessling; Heinz-Otto Keinecke; Jonathan A Bernstein Journal: J Allergy Clin Immunol Date: 2009-09-19 Impact factor: 10.793